L83 - Walk in LPL Dwarka-2 Plot No. 60, Sector 12B Dwarka New Delhi-110075 Delhi

.
L83 - WALK IN LPL DWARKA-2

Plot No. 60, Sector 12B Dwarka New
Delhi-110075
DELHI
Name : Mr. PRABHANJAN KUMAR Collected : 13/4/2022 8:21:00AM

Received : 13/4/2022 8:26:41AM
Lab No. : 161313066 Age: 39 Years Gender: Male Reported : 13/4/2022 6:10:08PM
A/c Status : P Ref By : CGHS Report Status : Final
Test Name Results Units Bio. Ref. Interval
HEMOGRAM
Hemoglobin** 13.30 g/dL 13.00 - 17.00

(Photometry)
Packed Cell Volume (PCV)** 42.90 % 40.00 - 50.00

(Calculated)
RBC Count** 4.47 mill/mm3 4.50 - 5.50

(Electrical Impedence)
MCV** 96.00 fL 83.00 - 101.00

MCH** 29.80 pg 27.00 - 32.00

(Calculated)
MCHC** 31.00 g/dL 31.50 - 34.50

(Calculated)
Red Cell Distribution Width (RDW)** 12.60 % 11.60 - 14.00

Total Leukocyte Count (TLC)** 7.77 thou/mm3 4.00 - 10.00

Differential Leucocyte Count (DLC)

(VCS Technology)
Segmented Neutrophils** 56.20 % 40.00 - 80.00
Lymphocytes** 33.70 % 20.00 - 40.00
Monocytes** 7.30 % 2.00 - 10.00
Eosinophils** 2.40 % 1.00 - 6.00
Basophils** 0.40 % <2.00
Absolute Leucocyte Count
(Calculated)
Neutrophils** 4.37 thou/mm3 2.00 - 7.00
Lymphocytes** 2.62 thou/mm3 1.00 - 3.00
Monocytes** 0.57 thou/mm3 0.20 - 1.00
Eosinophils** 0.19 thou/mm3 0.02 - 0.50
Basophils** 0.03 thou/mm3 0.02 - 0.10
Platelet Count** 342.0 thou/mm3 150.00 - 410.00
(Electrical impedence)
Mean Platelet Volume** 9.8 fL 6.5 - 12.0

ESR** 19 mm/hr 0.00 - 15.00

(Capillary photometry)
*161313066*
Page 1 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM

Note
1. As per the recommendation of International council for Standardization in Hematology, the differential
leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of
blood
2. Test conducted on EDTA whole blood
*161313066*
Page 2 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM
LIPID PROFILE, BASIC, SERUM**
Cholesterol Total** 123 mg/dL <200

(CHO-POD)
Triglycerides** 128 mg/dL <150

(GPO-POD)
HDL Cholesterol** 31 mg/dL >40

(Enz Immunoinhibition)
LDL Cholesterol,Direct** 80 mg/dL <100

(Enz Selective protection)
VLDL Cholesterol** 26 mg/dL <30

(Calculated)
Non-HDL Cholesterol** 92 mg/dL <130

(Calculated)
Interpretation
-----------------------------------------------------------------------------------
| NATIONAL LIPID | TOTAL | TRIGLYCERIDE | LDL CHOLESTEROL |NON HDL |
| ASSOCIATION | CHOLESTEROL | in mg/dL | in mg/dL |CHOLESTEROL |
| RECOMMENDATIONS | in mg/dL | | |in mg/dL |
| (NLA-2014) | | | | |
|-------------------|---------------|--------------|-----------------|--------------|
| Optimal | <200 | <150 | <100 | <130 |
|-------------------|---------------|--------------|-----------------|--------------|
| Above Optimal | - | - | 100- 129 | 130 - 159 |
|-------------------|---------------|--------------|-----------------|--------------|
| Borderline High | 200-239 | 150-199 | 130-159 | 160 - 189 |
|-------------------|---------------|--------------|-----------------|--------------|
| High | >=240 | 200-499 | 160-189 | 190 - 219 |
|-------------------|---------------|--------------|-----------------|--------------|
| Very High | - | >=500 | >=190 | >=220 |
-----------------------------------------------------------------------------------
Note
1. Measurements in the same patient can show physiological & analytical variations. Three serial
samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL
Cholesterol.
2. Lipid Association of India (LAI) recommends screening of all adults above the age of 20 years for
Atherosclerotic Cardiovascular Disease (ASCVD) risk factors especially lipid profile. This should be
PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)
*161313066*
Page 3 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM

done earlier if there is family history of premature heart disease, dyslipidemia, obesity or other risk
factors
3. Indians tend to have higher triglyceride levels & Lower HDL cholesterol combined with small dense
LDL particles, a pattern known as atherogenic dyslipidemia
4. Non HDL Cholesterol comprises the cholesterol carried by all atherogenic particles, including LDL,
IDL, VLDL & VLDL remnants, Chylomicron remnants & Lp(a)
5. The term LDL Cholesterol includes contribution of cholesterol from Lp(a), IDL & core LDL. Although
IDL and Lp(a) contributes only very few mg/dL to LDL cholesterol but their contribution can be
significant in patients with increased high IDL or Lp(a) concentration
6. LAI recommends LDL cholesterol as primary target and Non HDL cholesterol as co-primary
treatment target. The goal for Non HDL Cholesterol in those with increased triglyceride is 30 mg/dL
above that set for LDL Cholesterol.
7. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals
have been achieved
8. Additional testing for Apolipoprotein B, hsCRP, Lp(a ) & LP-PLA2 should be considered among
patients with moderate risk for ASCVD for risk refinement
Risk Stratification of ASCVD by Lipid Association of India 2016

-----------------------------------------------------------------------------------------------
| Major ASCVD Risk Factors |
|-----------------------------------------------------------------------------------------------|
| 1. Age >= 45 years in males and >= 55 years females |
| 2. Family h/o premature ASCVD(< 55 years of age in a male first degree relative or |
| <65 years of age in a female first degree relative) |
| 3. Current Cigarette smoking or tobacco use |
| 4. High blood pressure |
| 5. Low HDL |
|-----------------------------------------------------------------------------------------------|
| ASCVD Risk Categories |
|-----------------------------------------------------------------------------------------------|
| Risk Category | Conventional Risk markers | Non-Conventional Risk |
| | | markers (Optional) |
|---------------|------------------------------------------------|------------------------------|
| Very High | 1. Established ASCVD | None |
| Risk | 2. Diabetes with 2 or more major ASCVD risk | |
| | factors and/or evidence of end organ damage | |
| | 3. Familial Homozygous hypercholesterolemia | |
|---------------|------------------------------------------------|------------------------------|
| High Risk | | 1. Coronary artery calcium, |
| | 1. >=3 major ASCVD risk factors | CAC score >=300 AU |
| | 2. Diabetes with 0-1 major risk factor and no | 2. Lp(a)> = 50 mg/dL |
| | evidence of end organ damage | 3. Non stenotic carotid |
| | 3. CKD stage 3 B or 4 | plaque |
| | 4. Familial Hypercholesterolemia( other than | |
| | Familial Homozygous hypercholesterolemia) | |
| | 5. Extreme of a single factor e.g. LDL | |
| | Cholesterol >190 mg/dL,Heavy smoker, | |
| | strong family h/o premature ASCVD | |
*161313066*
Page 4 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM

|---------------|------------------------------------------------|------------------------------|
| Moderate risk | Any 2 major ASCVD risk factors | 1. Coronary artery calcium, |
| | | CAC score 100-299 AU |
| | | 2. Lp(a) 20-49 mg/dL |
| | | 3. Metabolic syndrome |
|---------------|------------------------------------------------|------------------------------|
| Low risk | 0-1 major ASCVD risk factors | None |
-----------------------------------------------------------------------------------------------
Treatment Goals as per Lipid Association of India 2016

-----------------------------------------------------------------------------------------
| | CONSIDER THERAPY | TREATMENT GOAL |
| |-------------------------------------|-------------------------------------|
| RISK CATEGORY| LDL CHOLESTEROL| NON HDL CHLOESTEROL| LDL CHOLESTEROL| NON HDL CHLOESTEROL|
| | (LDL-C)(mg/dL) | (NON HDL-C) (mg/dL)| (LDL-C)(mg/dL) |(NON HDL-C) (mg/dL |
|--------------|----------------|--------------------|----------------|--------------------|
| Very High | >=50 | >=80 | <50 | <80 |
|--------------|----------------|--------------------|----------------|--------------------|
| High | >=70 | >=100 | <70 | <100 |
|--------------|----------------|--------------------|----------------|--------------------|
| Moderate | >=100 | >=130 | <100 | <130 |
|--------------|----------------|--------------------|----------------|--------------------|
| Low | >=130* | >=160* | <100 | <130 |
------------------------------------------------------------------------------------------
* In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months
KIDNEY PANEL; KFT,SERUM
Urea** 23.50 mg/dL 13.00 - 43.00

(Urease UV)
Creatinine** 0.80 mg/dL 0.70 - 1.30

(Modified JaffeKinetic)
Uric Acid** 8.20 mg/dL 3.50 - 7.20

(Uricase)
Calcium, Total** 10.00 mg/dL 8.70 - 10.40

(Arsenazo III)
Phosphorus** 3.61 mg/dL 2.40 - 5.10

(Molybdate UV)
*161313066*
Page 5 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM

Alkaline Phosphatase (ALP)** 76.00 U/L 30.00 - 120.00
(IFCC-AMP)
Total Protein** 7.90 g/dL 5.70 - 8.20

(Biuret)
Albumin** 4.85 g/dL 3.20 - 4.80

(BCG)
A : G Ratio** 1.59 0.90 - 2.00

(Calculated)
Sodium** 141.00 mEq/L 136.00 - 145.00

(Indirect ISE)
Potassium** 4.36 mEq/L 3.50 - 5.10

(Indirect ISE)
Chloride** 108.00 mEq/L 98.00 - 107.00

(Indirect ISE)
*161313066*
Page 6 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM
PROTHROMBIN TIME STUDIES

(Electromechanical Clot Detection)
Mean Normal Prothrombin Time (PT) 13.50
Patient value 13.50 sec 11.30 - 15.60
Prothrombin Ratio (PR) 1.00
International Normalized Ratio (INR) 1.00 0.90 - 1.10
Note
1. INR is the parameter of choice in monitoring adequacy of oral anticoagulant therapy. Appropriate
therapeutic range varies with the disease and treatment intensity
2. Prolonged INR suggests potential bleeding disorder / bleeding complications
3. Results should be clinically correlated
4. Test conducted on Citrated plasma
Recommended Therapeutic range for Oral Anticoagulant therapy

INR 2.0-3.0 :
· Treatment of Venous thrombosis & Pulmonary embolism
· Prophylaxis of Venous thrombosis (High risk surgery)
· Prevention of systemic embolism in tissue heart valves, AMI, Valvular heart disease &
Atrial fibrillation
· Bileaflet mechanical valve in aortic position
INR 2.5-3.5:
§ Mechanical prosthetic valves
§ Systemic recurrent emboli
Comments
Prothrombin time measures the extrinsic coagulation pathway which consists of activated Factor VII (VIIa),
Tissue factor and Proteins of the common pathway (Factors X, V, II & Fibrinogen). This assay is used to
control long term oral anticoagulant therapy, evaluation of liver function & to evaluate coagulation disorders
specially factors involved in the extrinsic pathway like Factors V, VII, X, Prothrombin & Fibrinogen.
HEPATITIS B SURFACE ANTIGEN;HBsAg, SERUM** Non Reactive Non Reactive
(CLIA)
*Specific Antibody Neutralization Assay is performed on all Reactive results.

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)
*161313066*
Page 7 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM

Interpretation
-------------------------------------------------------------------
| RESULT | REMARKS |
|--------------|----------------------------------------------------|
| Reactive | Indicates presence of Hepatitis B Surface Antigen. |
|--------------|----------------------------------------------------|
| Non-Reactive | Indicates absence of Hepatitis B Surface Antigen. |
-------------------------------------------------------------------
Note
1. Reactive test result indicates presence of Hepatitis B Surface Antigen. It cannot differentiate between
the stages of Hepatitis B viral infection.
2. Non-Reactive test result indicates absence of Hepatitis B Surface Antigen.
3. False positive results may be observed in patients receiving mouse monoclonal antibodies, on
heparin therapy, on biotin supplements for diagnosis or therapy, in pregnancy, presence of
heterophilic antibodies in serum or after HBV vaccination for transient period of time.
4. False negative reaction may be due to processing of sample collected early in the course of disease
or presence of mutant forms of HBsAg .
5. For monitoring HBsAg levels, Quantitative HBsAg assay is recommended.
*161313066*
Page 8 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM

HEPATITIS C ANTIBODY (Anti-HCV), SERUM** 0.06 Index <1.00
(CMIA)
Interpretation
---------------------------------------------------------------------------------------------
| RESULT (INDEX) | REMARKS | INTERPRETATION |
|------------------|-----------------|--------------------------------------------------------|
| <1.00 | Non-Reactive | Indicates absence of antibodies to Hepatitis C virus |
|------------------|-----------------|--------------------------------------------------------|
| >=1.00 | Reactive | Indicates presence of antibodies to Hepatitis C virus. |
---------------------------------------------------------------------------------------------
Note
1. Reactive test result indicates presence of Hepatitis C virus infection. Active infection to be confirmed
by HCV RNA PCR test. It cannot differentiate between the stages of Hepatitis C viral infection nor
used to monitor the efficacy of treatment.
2. Low & High Reactive anti-HCV results are recommended to be evaluated by HCV RNA PCR studies.
3. Non-Reactive test result indicates Hepatitis C virus infection is unlikely.
4. False positive results may be observed in patients receiving mouse monoclonal antibodies, on
heparin therapy, on biotin supplements for diagnosis or therapy or presence of heterophilic antibodies
in serum.
5. False negative reaction may be due to processing of sample collected early in the course of disease,
Prozone phenomenon, Immunosuppression & Immuno-incompetence.
Uses
· To diagnose suspected HCV infection in risk group.
· Prenatal Screening of pregnant women and pre surgical/interventional procedures work up.
*161313066*
Page 9 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM
HIV 1 & 2 ANTIBODIES SCREENING TEST, SERUM**
-------------------------------
| Final Result : Negative |
-------------------------------
HIV 1 / 2 & P 24 COMBO TEST

(CMIA)
Index Value 0.06 Index <1.00
Result Negative
Interpretation
--------------------------------------------------------
| RESULT (INDEX) | REMARKS |
|------------------------|-------------------------------|
| >= 1.00 | Positive |
|------------------------|-------------------------------|
| < 1.00 | Negative |
--------------------------------------------------------
Note
1. Positive test result indicates antibody detected against HIV-1/2.
2. Negative test result indicates antibody is not detected against HIV- 1/2.
3. Indeterminate test result indicates antibody to HIV-1/2 have been detected in the sample by two of three
methods.
4. Results are reported as per the Strategy 3 of National guidelines of HIV testing by NACO, July 2015.
5. False positive results may be observed in Autoimmune diseases, Alcoholic hepatitis, Primary biliary
cirrhosis, Leprosy, Multiple pregnancies, Rheumatoid factor, and due to presence of heterophile
antibodies.
6. False negative results may occur during the window period and during the end stage of the disease.
Recommendations
1. Post-test counseling available between 9 am to 5 pm at LPL laboratories.
PatientReportSCSuperPanel.HIV_SC (Version: 6)
*161313066* Page 10 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM

HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD**
(HPLC, NGSP certified)
HbA1c** 7.9 % 4.00 - 5.60
Estimated average glucose (eAG)** 180 mg/dL
Interpretation
HbA1c result is suggestive of Diabetes/ Higher than glycemic goal in a known Diabetic patient.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy,
comorbid conditions, known CVD or advanced microvascular complications, hypoglycaemia unawareness,
and individual patient considerations
Result Rechecked,
Please Correlate Clinically.
Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered,
particularly when the HbA1C result does not correlate with the patient’s blood glucose levels.
---------------------------------------------------------------------------------
| FACTORS THAT INTERFERE WITH HbA1C | FACTORS THAT AFFECT INTERPRETATION |
| MEASUREMENT | OF HBA1C RESULTS |
|--------------------------------------|------------------------------------------|
| Hemoglobin variants,elevated fetal | Any condition that shortens erythrocyte |
| hemoglobin (HbF) and chemically | survival or decreases mean erythrocyte |
| modified derivatives of hemoglobin | age (e.g.,recovery from acute blood loss,|
| (e.g. carbamylated Hb in patients | hemolytic anemia, HbSS, HbCC, and HbSC) |
| with renal failure) can affect the | will falsely lower HbA1c test results |
| accuracy of HbA1c measurements | regardless of the assay method used.Iron |
| | deficiency anemia is associated with |
| | higher HbA1c |
---------------------------------------------------------------------------------
PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)
*161313066*
Page 11 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM

BLOOD PICTURE; PERIPHERAL BLOOD SMEAR Predominantly normocytic normochromic RBCs.
EXAMINATION** WBCs are normal in number and morphology.
(Microscopy) No abnormal/immature cells seen .
Platelets are adequate.
No Hemoparasites seen
Followup and clinical correlation
PatientReportSCSuperPanel.GENERAL_METHOD_SC (Version: 6)
*161313066*
Page 12 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM
GLUCOSE, FASTING (F) AND POST MEAL, PLASMA

(Hexokinase)
Glucose Fasting** 126.00 mg/dL 70 - 100
Glucose (PP) Sample Not Received

SNR01-
Dr Ajay Gupta Dr Gurleen Oberoi Dr Jatin Munjal Dr.Kamal Modi

MD, Pathology DM(Hematopathology), MD, MD,Pathology MD, Biochemistry
Technical Director - Hematology & DNB,MNAMS Consultant Pathologist Consultant Biochemist
Immunology Consultant & Technical Lead Dr Lal PathLabs Ltd NRL - Dr Lal PathLabs Ltd
NRL - Dr Lal PathLabs Ltd -Hematopathology
NRL - Dr Lal PathLabs Ltd
Dr Sarita Kumari Lal Dr Himangshu Mazumdar

MD, Pathology MD, Biochemistry
Consultant Pathologist Sr. Consultant Biochemist
Dr Lal PathLabs Ltd NRL - Dr Lal PathLabs Ltd
Dr Nimmi Kansal
MD, Biochemistry
Technical Director - Clinical Chemistry
& Biochemical Genetics
NRL - Dr Lal PathLabs Ltd
-------------------------------End of report --------------------------------
AHEEEHAPMKHLFPGNLLKAIJNCBILLJCECCIJCIKPLPKEDFIFAPPAHEEEHA
BNFFFNBPAPBOFKFGFOEGEGAPAOAHFHALBGJOBCJCNLELMOJHNPBNFFFNB
GIEHBBFPPPPAMBEJEFIAAJHFJAFEHEDBNKPHENFLMKKCKEFLBLHDEHANP
DJHMLIFNBMKIEPELEJOELGOFAFHLBKBFJIFEPBOAKODJPDNLIHNBKEMEL
KCMIBJFJPFFFDIAFFGIFILBEIENLKLKHKKMNGMMIPLKGKPNGKFFFOOKFH
NLCBBEFPIEOJOIHKICKGBIPBADHFOFAINDFCBKDLBLIKOMNALNEIOOEKL
CNIMIJFJILOKLCCIEGMLBFEHIHAFJBALPFMPBLMKOJCGKNHCIJNJMDILD
FJHBAMFNBLNJDLKPFANHDBOILLBMFMBHKFCCAMNNIIKJOPNOBNFMAHILL
NKLKJJFHOONGFEMFFOPIHHEKHEFFEKFBJFFLALPFOEDIOCNKDJPHNEKLJ
NMOJJEFCEAMJJDCLIGJJDLFNKDFKPNJHKEPHCFNKNKCKIGEOCCOKHMALK
DJIKDPFLGKKECMDMPCFNFJEEINMGGEABJMEEBFOCONDMKPFKEPCIGCAMO
IOICGJFDGLDOEEPMHHKLMNBEIEOPPFOEAONPBLNOOLJBIMFINKONHDICL
MNNNNNEPCFAOJPAEPCFLHEKHJBAHFHAPNKPFCMNLMLIILFNNAHFHAHIKL
APBBBPAPBOKAEFFLLNAKCIJFAEGCHHCAONFEPLPGODKHNLNNEDFGCBKHH
HHHHHHHPHHHPHPPHPPHHPPPPHHPPPPPPPPPHHPHPPHHHPHPHHHHHHHPHP
*161313066*
Page 13 of 14
.

Delhi-110075
DELHI

Received : 13/4/2022 8:26:41AM
** Test conducted under NABL scope MC-2113,LPL-NATIONAL REFERENCE LAB at NEW DELHI
IMPORTANT INSTRUCTIONS
ŸTest results released pertain to the specimen submitted .ŸAll test results are dependent on the quality of the sample received by the Laboratory .
ŸLaboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring
Physician.ŸSample repeats are accepted on request of Referring Physician within 7 days post reporting.ŸReport delivery may be delayed due to
unforeseen circumstances. Inconvenience is regretted .ŸCertain tests may require further testing at additional cost for derivation of exact value .
Kindly submit request within 72 hours post reporting.ŸTest results may show interlaboratory variations .ŸThe Courts/Forum at Delhi shall have
exclusive jurisdiction in all disputes /claims concerning the test(s) & or results of test(s).ŸTest results are not valid for medico legal purposes .
ŸContact customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
*161313066*
Page 14 of 14

L83 - Walk in LPL Dwarka-2 Plot No. 60, Sector 12B Dwarka New Delhi-110075 Delhi

Uploaded by

Copyright:

Available Formats

L83 - Walk in LPL Dwarka-2 Plot No. 60, Sector 12B Dwarka New Delhi-110075 Delhi

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

L83 - Walk in LPL Dwarka-2 Plot No. 60, Sector 12B Dwarka New Delhi-110075 Delhi

Uploaded by

Copyright:

Available Formats

.

L83 - WALK IN LPL DWARKA-2

Name : Mr. PRABHANJAN KUMAR Collected : 13/4/2022 8:21:00AM

Test Name Results Units Bio. Ref. Interval

Hemoglobin** 13.30 g/dL 13.00 - 17.00

Packed Cell Volume (PCV)** 42.90 % 40.00 - 50.00

RBC Count** 4.47 mill/mm3 4.50 - 5.50

MCV** 96.00 fL 83.00 - 101.00

MCH** 29.80 pg 27.00 - 32.00

MCHC** 31.00 g/dL 31.50 - 34.50

Red Cell Distribution Width (RDW)** 12.60 % 11.60 - 14.00

Total Leukocyte Count (TLC)** 7.77 thou/mm3 4.00 - 10.00

Differential Leucocyte Count (DLC)

Mean Platelet Volume** 9.8 fL 6.5 - 12.0

ESR** 19 mm/hr 0.00 - 15.00

L83 - WALK IN LPL DWARKA-2

Name : Mr. PRABHANJAN KUMAR Collected : 13/4/2022 8:21:00AM

Test Name Results Units Bio. Ref. Interval

2. Test conducted on EDTA whole blood

L83 - WALK IN LPL DWARKA-2

Name : Mr. PRABHANJAN KUMAR Collected : 13/4/2022 8:21:00AM

Test Name Results Units Bio. Ref. Interval

LIPID PROFILE, BASIC, SERUM**

Cholesterol Total** 123 mg/dL <200

Triglycerides** 128 mg/dL <150

HDL Cholesterol** 31 mg/dL >40

LDL Cholesterol,Direct** 80 mg/dL <100

VLDL Cholesterol** 26 mg/dL <30

Non-HDL Cholesterol** 92 mg/dL <130

L83 - WALK IN LPL DWARKA-2

Name : Mr. PRABHANJAN KUMAR Collected : 13/4/2022 8:21:00AM

Test Name Results Units Bio. Ref. Interval

Risk Stratification of ASCVD by Lipid Association of India 2016

L83 - WALK IN LPL DWARKA-2

Name : Mr. PRABHANJAN KUMAR Collected : 13/4/2022 8:21:00AM

Test Name Results Units Bio. Ref. Interval

Treatment Goals as per Lipid Association of India 2016

KIDNEY PANEL; KFT,SERUM

Urea** 23.50 mg/dL 13.00 - 43.00

Creatinine** 0.80 mg/dL 0.70 - 1.30

Uric Acid** 8.20 mg/dL 3.50 - 7.20

Calcium, Total** 10.00 mg/dL 8.70 - 10.40

Phosphorus** 3.61 mg/dL 2.40 - 5.10

L83 - WALK IN LPL DWARKA-2

Name : Mr. PRABHANJAN KUMAR Collected : 13/4/2022 8:21:00AM

Test Name Results Units Bio. Ref. Interval

Total Protein** 7.90 g/dL 5.70 - 8.20

Albumin** 4.85 g/dL 3.20 - 4.80

A : G Ratio** 1.59 0.90 - 2.00

Sodium** 141.00 mEq/L 136.00 - 145.00

Potassium** 4.36 mEq/L 3.50 - 5.10

Chloride** 108.00 mEq/L 98.00 - 107.00

L83 - WALK IN LPL DWARKA-2

Name : Mr. PRABHANJAN KUMAR Collected : 13/4/2022 8:21:00AM

Test Name Results Units Bio. Ref. Interval

PROTHROMBIN TIME STUDIES

Mean Normal Prothrombin Time (PT) 13.50

Patient value 13.50 sec 11.30 - 15.60

Prothrombin Ratio (PR) 1.00